Posters

Intravitreal injection of Conbercept is not correlated with progression of macular retinoschisis in myopic choroidal neovascularization patients

Poster Details

First Author: X.Sun CHINA

Co Author(s):    Y. Zhou   S. Yang   F. Wang                       

Abstract Details



Purpose:

To describe the association between intravitreal injection of Conbercept and development of myopic macular retinoschisis (MRS) in myopic choroidal neovascularization (mCNV) patients

Setting:

A retrospective, consecutive case series.

Methods:

We retrospectively observed the records of 114 consecutive pathological myopic patients with active mCNV. Demographic and tomographic data were carefully reviewed. There were two treatment strategies for the whole patients. One group of patients got intravitreal Conbercept injections monthly for 3 months and then administrated if pro re nata (PRN). Another group of patients got non-injection monthly for 3 months and then got intravitreal injection of Conbercept if needed. All the patients were followed for 9 months. The monthly OCT images were evaluated for the presence of the extent and height of MRS, retinal thickness and tomographic characteristics by two independent graders.

Results:

Thirty-four of 114 mCNV eyes (29.8%) had preexisted MRS. 2 eyes (1.8%) had new onset of MRS after 9 month follow up. Baseline characteristics including the age, gender, axial length, best corrected visual acuity (BCVA), central retinal thickness and the severe chorioretinopathy were not statistically different between eyes with and without MRS (P > 0.05). 11 of 36 eyes had MRS progression after 9 month follow up. Both eyes with progressed and non-progressed MRS had well controlled mCNV after Conbercept therapy. Moreover, there were no statistical difference of the height of MRS increase, the number of intravitreal injections and the number of eyes having 3+PRN treatment strategy between progressed and non-progressed MRS eyes. Furthermore, there was no statistical difference of MRS progression between Conbercept injected eyes and non-injected eyes at the end of 3 months (P = 0.634), so was the mean height of MRS increase (P = 0.748). Binary logistics regression demonstrated that the preexisted partial PVD may increase the risk factor of MRS progression (OR = 5.470, P = 0.044) rather than the intravitreal injection procedure (P > 0.05).

Conclusions:

Macular retinoschsis in mCNV patients are not rare. A 9 months’ follow-up shows intravitreal injection of Conbercept may not be correlated with MRS progression in myopic CNV eyes.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy